110 related articles for article (PubMed ID: 23230603)
1. Retraction notice to "Redox regulation of angiotensin II preconditioning of the myocardium requires MAP kinase signaling" [J. Mol. Cell. Cardiol. 41 (2006) 248–255].
J Mol Cell Cardiol; 2012 Nov; 53(5):742. PubMed ID: 23230603
[No Abstract] [Full Text] [Related]
2. Redox regulation of angiotensin II preconditioning of the myocardium requires MAP kinase signaling.
Das S; Otani H; Maulik N; Das DK
J Mol Cell Cardiol; 2006 Aug; 41(2):248-55. PubMed ID: 16697003
[TBL] [Abstract][Full Text] [Related]
3. Retraction notice to "Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target" [J. Mol. Cell. Cardiol. 42 (2007) 981–990].
J Mol Cell Cardiol; 2012 Nov; 53(5):743. PubMed ID: 23230604
[No Abstract] [Full Text] [Related]
4. Retraction notice to "Role of glutaredoxin-1 in cardioprotection: an insight with Glrx1 transgenic and knockout animals" [J. Mol. Cell. Cardiol. 44 (2008) 261–269].
J Mol Cell Cardiol; 2012 Nov; 53(5):745. PubMed ID: 23230606
[No Abstract] [Full Text] [Related]
5. Retraction notice to "Overexpression of glutaredoxin-2 reduces myocardial cell death by preventing both apoptosis and necrosis" [J. Mol. Cell. Cardiol. 44 (2008) 252–260].
J Mol Cell Cardiol; 2012 Nov; 53(5):744. PubMed ID: 23230605
[No Abstract] [Full Text] [Related]
6. Angiotensin preconditioning of the heart: evidence for redox signaling.
Das S; Engelman RM; Maulik N; Das DK
Cell Biochem Biophys; 2006; 44(1):103-10. PubMed ID: 16456238
[TBL] [Abstract][Full Text] [Related]
7. Src family kinase and adenosine differentially regulate multiple MAP kinases in ischemic myocardium: modulation of MAP kinases activation by ischemic preconditioning.
Takeishi Y; Huang Q; Wang T; Glassman M; Yoshizumi M; Baines CP; Lee JD; Kawakatsu H; Che W; Lerner-Marmarosh N; Zhang C; Yan C; Ohta S; Walsh RA; Berk BC; Abe J
J Mol Cell Cardiol; 2001 Nov; 33(11):1989-2005. PubMed ID: 11708843
[TBL] [Abstract][Full Text] [Related]
8. Retraction notice to "Ivabradine as adjuvant treatment for chronic heart failure" [Int. J. Cardiol. 227 (2017) 43-50].
Mizzaci CC; Porfírio GJM; Vilela AT; Guillhen JCS; Riera R
Int J Cardiol; 2017 Nov; 247():55. PubMed ID: 28916091
[No Abstract] [Full Text] [Related]
9. Retraction notice to "Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury" [Int. J. Cardiol. 163 (2013) 326-334].
Barry SP; Ounzain S; McCormick J; Scarabelli TM; Chen-Scarabelli C; Saravolatz LII; Faggian G; Mazzucco A; Suzuki H; Thiemermann C; Knight RA; Latchman DS; Stephanou A
Int J Cardiol; 2019 Jan; 274():404. PubMed ID: 30449337
[No Abstract] [Full Text] [Related]
10. Retraction notice to Diagnosis of Microvascular Angina Using Cardiac Magnetic Resonance: J Am Coll Cardiol 71 (2018) 969-979.
Liu A; Wijesurendra RS; Liu JM; Forfar JC; Channon KM; Jerosch-Herold M; Piechnik SK; Neubauer S; Kharbanda RK; Ferreira VM
J Am Coll Cardiol; 2020 Oct; 76(16):1916. PubMed ID: 33059840
[No Abstract] [Full Text] [Related]
11. Retraction notice to Mapping the Future of Myocardial Ischemia Testing With Cardiac Magnetic Resonance: J Am Coll Cardiol 71 (2018) 980-982.
Karamitsos TD
J Am Coll Cardiol; 2020 Oct; 76(16):1917. PubMed ID: 33059841
[No Abstract] [Full Text] [Related]
12. Retraction notice to "Prognostic factors for the long-term survival in patients with vasospastic angina--Analysis of effects of patients' characteristics and therapeutic drugs" [J Cardiol 54 (2009) 10-20].
J Cardiol; 2010 Mar; 55(2):285. PubMed ID: 20684042
[No Abstract] [Full Text] [Related]
13. Retraction notice to Gadolinium-Free Cardiac MR Stress T1-Mapping to Distinguish Epicardial From Microvascular Coronary Disease: J Am Coll Cardiol 71 (2018) 957-968.
Liu A; Wijesurendra RS; Liu JM; Greiser A; Jerosch-Herold M; Forfar JC; Channon KM; Piechnik SK; Neubauer S; Kharbanda RK; Ferreira VM
J Am Coll Cardiol; 2020 Oct; 76(16):1915. PubMed ID: 33059839
[No Abstract] [Full Text] [Related]
14. Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation.
Touyz RM; Cruzado M; Tabet F; Yao G; Salomon S; Schiffrin EL
Can J Physiol Pharmacol; 2003 Feb; 81(2):159-67. PubMed ID: 12710530
[TBL] [Abstract][Full Text] [Related]
15. MAP kinase-independent signaling in angiotensin II regulation of neuromodulation in SHR neurons.
Yang H; Raizada MK
Hypertension; 1998 Sep; 32(3):473-81. PubMed ID: 9740613
[TBL] [Abstract][Full Text] [Related]
16. Preconditioning by angiotensin II: a tale of more than two kinases.
Dawn B
J Mol Cell Cardiol; 2006 Aug; 41(2):223-5. PubMed ID: 16793059
[No Abstract] [Full Text] [Related]
17. Caveolin and MAP kinase interaction in angiotensin II preconditioning of the myocardium.
Das M; Das S; Das DK
J Cell Mol Med; 2007; 11(4):788-97. PubMed ID: 17760840
[TBL] [Abstract][Full Text] [Related]
18. Role of p38 MAP kinase in myocardial stress.
Nagarkatti DS; Sha'afi RI
J Mol Cell Cardiol; 1998 Aug; 30(8):1651-64. PubMed ID: 9841266
[TBL] [Abstract][Full Text] [Related]
19. Retraction of "Song ZZ, Resynchronization of the infarcted myocardium. Int J Cardiol. 2009 Jan 9. [Epub ahead of print]" containing plagiarised material.
Coats AJ
Int J Cardiol; 2009 May; 134(2):149. PubMed ID: 19344963
[No Abstract] [Full Text] [Related]
20. Angiotensin II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts.
Schorb W; Conrad KM; Singer HA; Dostal DE; Baker KM
J Mol Cell Cardiol; 1995 May; 27(5):1151-60. PubMed ID: 7473773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
